Biohaven Q2 net loss narrows on lower R&D spend

Biohaven

10/08/2026 21:09

Overview
U.S. biopharma firm's Q2 net loss narrowed yr/yr on lower R&D and preclinical spending
Q2 operating expenses fell sharply after strategic reprioritization of programs
Company advanced pivotal trials in Graves disease and IgA nephropathy, with multiple pipeline updates

Outlook
Company expects topline results from Phase 2/3 RISE3 epilepsy trial in 2H 2026
Biohaven plans to initiate pivotal Phase 3 study for BHV-1400 in IgAN in 2H 2026
Company expects topline data from Phase 2 obesity study with taldefgrobep alfa in 2H 2026

Result Drivers
R&D EXPENSE REDUCTION - Co attributed lower Q2 R&D expenses to strategic reprioritization of programs and absence of prior-year milestone payments
G&A COST SAVINGS - Lower Q2 general and administrative expenses driven by reduced legal and employee costs

Company press release: ID:nPnbx3Y2ya

Key Details
Metric
Beat/Miss
Actual
Consensus Estimate
Q2 Net Loss
 
$137.31 mln
 
Q2 Loss Per Basic Share
 
$0.91
 
Q2 Operating Expenses
 
$124.90 mln
 
Q2 Profit From Operations
 
-$124.90 mln
 

Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 13 "strong buy" or "buy", 3 "hold" and 1 "sell" or "strong sell"
The average consensus recommendation for the biotechnology & medical research peer group is "buy"
Wall Street's median 12-month price target for Biohaven Ltd. is $20.50, about 39.8% above its August 7 closing price of $14.66

Reuters Recommended Reads
Aug 10 - Cogent Biosciences Q2 net loss widens on higher expenses
Aug 10 - CervoMed Q2 net loss lower than estimates as costs drop
Aug 10 - Ireland's Theravance Biopharma Q2 revenue rises 11% but misses estimates

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)